The mitochondrial cocktail: Rationale for combined nutraceutical therapy in mitochondrial cytopathies

Advanced Drug Delivery Reviews

Volumn 60, Issue 13-14, 2008, Pages 1561-1567

  Tarnopolsky, M A ^a  

^a MCMASTER UNIVERSITY   (Canada)

Author keywords

Antioxidant; LHON; MELAS; Mitochondrial myopathy; Neuroprotection

Indexed keywords

CELL DEATH;

ANTIOXIDANT; LHON; MELAS; MITOCHONDRIAL MYOPATHY; NEUROPROTECTION;

CHLORINE COMPOUNDS;

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BIOTIN; CARNITINE; CREATINE; FOLIC ACID; METHYLPREDNISOLONE; NICOTINIC ACID; NUTRACEUTICAL; PANTOTHENIC ACID; PYRIDOXINE; RIBOFLAVIN; THIAMINE; THIOCTIC ACID; UBIDECARENONE; UBIQUINOL CYTOCHROME C REDUCTASE; VITAMIN K GROUP;

CLINICAL TRIAL; DIET SUPPLEMENTATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; HUMAN; KEARNS SAYRE SYNDROME; LEBER HEREDITARY OPTIC NEUROPATHY; MELAS SYNDROME; NEUROPROTECTION; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; VITAMIN SUPPLEMENTATION;

ANTIOXIDANTS; COENZYMES; CREATINE; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; ENERGY METABOLISM; HUMANS; MITOCHONDRIA; MITOCHONDRIAL DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; THIOCTIC ACID;

EID: 51249120293     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2008.05.001     Document Type: Review

References (120)

1. Tarnopolsky M.A., and Beal M.F. Potential for creatine and other therapies targeting cellular energy dysfunction in neurological disorders. Ann. Neurol. 49 (2001) 561-574
2. Priault M., Salin B., Schaeffer J., Vallette F.M., di Rago J.P., and Martinou J.C. Impairing the bioenergetic status and the biogenesis of mitochondria triggers mitophagy in yeast. Cell Death Differ. 12 (2005) 1613-1621
3. Harman D. Free radical theory of aging: an update: increasing the functional life span. Ann. N. Y. Acad. Sci. 1067 (2006) 10-21
4. Sanz A., Pamplona R., and Barja G. Is the mitochondrial free radical theory of aging intact?. Antioxid. Redox Signal. 8 (2006) 582-599
5. Kelley D.E., He J., Menshikova E.V., and Ritov V.B. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51 (2002) 2944-2950
6. Ritov V., Menshikova E., He J., Ferrel R., Goodpaster B., and Kelley D. Deficiency of subsarcolemmal mitochondria in obesity and type 2 diabetes. Diabetes 54 (2005) 8-14
7. Cassina P., Cassina A., Pehar M., Castellanos R., Gandelman M., de Leon A., Robinson K.M., Mason R.P., Beckman J.S., Barbeito L., and Radi R. Mitochondrial dysfunction in SOD1G93A-bearing astrocytes promotes motor neuron degeneration: prevention by mitochondrial-targeted antioxidants. J. Neurosci. 28 (2008) 4115-4122
8. Beal M.F. Mitochondria and neurodegeneration. Novartis Found. Symp. 287 (2007) 183-192 discussion 192-186
9. Beal M.F. Mitochondria take center stage in aging and neurodegeneration. Ann. Neurol. 58 (2005) 495-505
10. Albers D.S., and Beal M.F. Mitochondrial dysfunction and oxidative stress in aging and neurodegenerative disease. J. Neural. Transm. Suppl. 59 (2000) 133-154
11. Passos J.F., Saretzki G., and von Zglinicki T. DNA damage in telomeres and mitochondria during cellular senescence: is there a connection?. Nucleic Acids Res 35 (2007) 7505-7513
12. Trushina E., and McMurray C.T. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 145 (2007) 1233-1248
13. Raha S., and Robinson B.H. Mitochondria, oxygen free radicals, disease and ageing. Trends Biochem. Sci. 25 (2000) 502-508
14. Grivennikova V.G., and Vinogradov A.D. Generation of superoxide by the mitochondrial complex I. Biochim. Biophys. Acta 1757 (2006) 553-561
15. Muller F.L., Liu Y., and Van Remmen H. Complex III releases superoxide to both sides of the inner mitochondrial membrane. J. Biol. Chem. 279 (2004) 49064-49073
16. Raha S., Myint A.T., Johnstone L., and Robinson B.H. Control of oxygen free radical formation from mitochondrial complex I: roles for protein kinase A and pyruvate dehydrogenase kinase. Free Radic Biol Med 32 (2002) 421-430
17. St-Pierre J., Buckingham J.A., Roebuck S.J., and Brand M.D. Topology of superoxide production from different sites in the mitochondrial electron transport chain. J. Biol. Chem. 277 (2002) 44784-44790
18. Raha S., McEachern G.E., Myint A.T., and Robinson B.H. Superoxides from mitochondrial complex III: the role of manganese superoxide dismutase. Free Radic. Biol. Med. 29 (2000) 170-180
19. Tan G., Chen L.S., Lonnerdal B., Gellera C., Taroni F.A., and Cortopassi G.A. Frataxin expression rescues mitochondrial dysfunctions in FRDA cells. Hum. Mol. Genet. 10 (2001) 2099-2107
20. Battisti C., Formichi P., Cardaioli E., Bianchi S., Mangiavacchi P., Tripodi S.A., Tosi P., and Federico A. Cell response to oxidative stress induced apoptosis in patients with Leber's hereditary optic neuropathy. J. Neurol. Neurosurg. Psychiatry 75 (2004) 1731-1736
21. Canter J.A., Eshaghian A., Fessel J., Summar M.L., Roberts L.J., Morrow J.D., Sligh J.E., and Haines J.L. Degree of heteroplasmy reflects oxidant damage in a large family with the mitochondrial DNA A8344G mutation. Free Radic. Biol. Med. 38 (2005) 678-683
22. Di Giovanni S., Mirabella M., Papacci M., Odoardi F., Silvestri G., and Servidei S. Apoptosis and ROS detoxification enzymes correlate with cytochrome c oxidase deficiency in mitochondrial encephalomyopathies. Mol. Cell. Neurosci. 17 (2001) 696-705
23. Esposito L.A., Melov S., Panov A., Cottrell B.A., and Wallace D.C. Mitochondrial disease in mouse results in increased oxidative stress. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 4820-4825
24. Kunishige M., Mitsui T., Akaike M., Kawajiri M., Shono M., Kawai H., and Matsumoto T. Overexpressions of myoglobin and antioxidant enzymes in ragged-red fibers of skeletal muscle from patients with mitochondrial encephalomyopathy. Muscle Nerve 28 (2003) 484-492
25. Tarnopolsky M.A., Simon D., Roy B., Chorneyko K., Lowther S., and Johns D. Attenuation of free radical production and paracrystalline inclusions by creatine supplementation in a patient with a novel cytochrome b mutation. Muscle Nerve 29 (2004) 537-547
26. St Clair D.K., Porntadavity S., Xu Y., and Kiningham K. Transcription regulation of human manganese superoxide dismutase gene. Methods Enzymol. 349 (2002) 306-312
27. Floreani M., Napoli E., Martinuzzi A., Pantano G., De Riva V., Trevisan R., Bisetto E., Valente L., Carelli V., and Dabbeni-Sala F. Antioxidant defences in cybrids harboring mtDNA mutations associated with Leber's hereditary optic neuropathy. FEBS J. 272 (2005) 1124-1135
28. Jialal I., and Devaraj S. Scientific evidence to support a vitamin E and heart disease health claim: research needs. J. Nutr. 135 (2005) 348-353
29. Pruthi S., Allison T.G., and Hensrud D.D. Vitamin E supplementation in the prevention of coronary heart disease. Mayo Clin. Proc. 76 (2001) 1131-1136
30. Lonn E., Yusuf S., Hoogwerf B., Pogue J., Yi Q., Zinman B., Bosch J., Dagenais G., Mann J.F., and Gerstein H.C. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. Diabetes Care 25 (2002) 1919-1927
31. Lonn E., Bosch J., Yusuf S., Sheridan P., Pogue J., Arnold J.M., Ross C., Arnold A., Sleight P., Probstfield J., and Dagenais G.R. Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. JAMA 293 (2005) 1338-1347
32. Rodriguez M.C., MacDonald J.R., Mahoney D.J., Parise G., Beal M.F., and Tarnopolsky M.A. Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders. Muscle Nerve 35 (2007) 235-242
33. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8, Arch Ophthalmol 119 (2001) 1417-1436.
34. Milton R.C., Sperduto R.D., Clemons T.E., and Ferris 3rd F.L. Centrum use and progression of age-related cataract in the Age-Related Eye Disease Study: a propensity score approach. AREDS report No. 21. Ophthalmology 113 (2006) 1264-1270
35. Chucair A.J., Rotstein N.P., Sangiovanni J.P., During A., Chew E.Y., and Politi L.E. Lutein and zeaxanthin protect photoreceptors from apoptosis induced by oxidative stress: relation with docosahexaenoic acid. Invest. Ophthalmol. Vis. Sci. 48 (2007) 5168-5177
36. Tan J.S., Wang J.J., Flood V., Rochtchina E., Smith W., and Mitchell P. Dietary antioxidants and the long-term incidence of age-related macular degeneration: the Blue Mountains Eye Study. Ophthalmology 115 (2008) 334-341
37. Dimauro S., Mancuso M., and Naini A. Mitochondrial encephalomyopathies: therapeutic approach. Ann. N. Y. Acad. Sci. 1011 (2004) 232-245
38. DiMauro S., Hirano M., and Schon E.A. Approaches to the treatment of mitochondrial diseases. Muscle Nerve 34 (2006) 265-283
39. Geromel V., Darin N., Chretien D., Benit P., DeLonlay P., Rotig A., Munnich A., and Rustin P. Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol. Genet. Metab. 77 (2002) 21-30
40. Mahoney D.J., Parise G., and Tarnopolsky M.A. Nutritional and exercise-based therapies in the treatment of mitochondrial disease. Curr. Opin. Clin. Nutr. Metab. Care 5 (2002) 619-629
41. Marriage B., Clandinin M.T., and Glerum D.M. Nutritional cofactor treatment in mitochondrial disorders. J. Am. Diet. Assoc. 103 (2003) 1029-1038
42. Tarnopolsky M.A., and Raha S. Mitochondrial myopathies: diagnosis, exercise intolerance, and treatment options. Med. Sci. Sports Exerc. 37 (2005) 2086-2093
43. Panigrahi M., Sadguna Y., Shivakumar B.R., Kolluri S.V., Roy S., Packer L., and Ravindranath V. Alpha-lipoic acid protects against reperfusion injury following cerebral ischemia in rats. Brain Res. 717 (1996) 184-188
44. Andreassen O.A., Ferrante R.J., Dedeoglu A., and Beal M.F. Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 12 (2001) 3371-3373
45. Hagen T.M., Ingersoll R.T., Lykkesfeldt J., Liu J., Wehr C.M., Vinarsky V., Bartholomew J.C., and Ames A.B. (R)-alpha-lipoic acid-supplemented old rats have improved mitochondrial function, decreased oxidative damage, and increased metabolic rate. FASEB J. 13 (1999) 411-418
46. Burke D.G., Chilibeck P.D., Parise G., Tarnopolsky M.A., and Candow D.G. Effect of alpha-lipoic acid combined with creatine monohydrate on human skeletal muscle creatine and phosphagen concentration. Int. J. Sport Nutr. Exerc. Metab. 13 (2003) 294-302
47. Barbiroli B., Medori R., Tritschler H.J., Klopstock T., Seibel P., Reichmann H., Iotti S., Lodi R., and Zaniol P. Lipoic (thioctic) acid increases brain energy availability and skeletal muscle performance as shown by in vivo 31P-MRS in a patient with mitochondrial cytopathy. J. Neurol. 242 (1995) 472-477
48. Foster T.S. Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy. Diabetes Educ. 33 (2007) 111-117
49. Kamenova P. Improvement of insulin sensitivity in patients with type 2 diabetes mellitus after oral administration of alpha-lipoic acid. Hormones (Athens) 5 (2006) 251-258
50. Ziegler D. Thioctic acid for patients with symptomatic diabetic polyneuropathy: a critical review. Treat. Endocrinol. 3 (2004) 173-189
51. Ziegler D. Treatment of diabetic polyneuropathy: update 2006. Ann. N. Y. Acad. Sci. 1084 (2006) 250-266
52. Tarnopolsky M., Stevens L., MacDonald J.R., Rodriguez C., Mahoney D., Rush J., and Maguire J. Diagnostic utility of a modified forearm ischemic exercise test and technical issues relevant to exercise testing. Muscle Nerve 27 (2003) 359-366
53. Terjung R.L., Clarkson P., Eichner E.R., Greenhaff P.L., Hespel P.J., Israel R.G., Kraemer W.J., Meyer R.A., Spriet L.L., Tarnopolsky M.A., Wagenmakers A.J., and Williams M.H. American College of Sports Medicine roundtable. The physiological and health effects of oral creatine supplementation. Med. Sci. Sports Exerc. 32 (2000) 706-717
54. Wyss M., and Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol. Rev. 80 (2000) 1107-1213
55. Rango M., Bozzali M., Prelle A., Scarlato G., and Bresolin N. Brain activation in normal subjects and in patients affected by mitochondrial disease without clinical central nervous system involvement: a phosphorus magnetic resonance spectroscopy study. J. Cereb. Blood Flow Metab. 21 (2001) 85-91
56. Tarnopolsky M.A., and Parise G. Direct measurement of high-energy phosphate compounds in patients with neuromuscular disease. Muscle Nerve 22 (1999) 1228-1233
57. Matthews P.M., Allaire C., Shoubridge E.A., Karpati G., Carpenter S., and Arnold D.L. In vivo muscle magnetic resonance spectroscopy in the clinical investigation of mitochondrial disease. Neurology 41 (1991) 114-120
58. Argov Z., Lofberg M., and Arnold D.L. Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy. Muscle Nerve 23 (2000) 1316-1334
59. Lodi R., Montagna P., Iotti S., Zaniol P., Barboni P., Puddu P., and Barbiroli B. Brain and muscle energy metabolism studied in vivo by 31P-magnetic resonance spectroscopy in NARP syndrome. J. Neurol. Neurosurg. Psychiatry 57 (1994) 1492-1496
60. Brose A., Parise G., and Tarnopolsky M.A. Creatine supplementation enhances isometric strength and body composition improvements following strength exercise training in older adults. J. Gerontol. A Biol. Sci. Med. Sci. 58 (2003) 11-19
61. Harris R.C., Soderlund K., and Hultman E. Elevation of creatine in resting and exercised muscle of normal subjects by creatine supplementation. Clin. Sci. (Lond) 83 (1992) 367-374
62. Hultman E., Soderlund K., Timmons J.A., Cederblad G., and Greenhaff P.L. Muscle creatine loading in men. J. Appl. Physiol. 81 (1996) 232-237
63. Parise G., Mihic S., MacLennan D., Yarasheski K.E., and Tarnopolsky M.A. Effects of acute creatine monohydrate supplementation on leucine kinetics and mixed-muscle protein synthesis. J. Appl. Physiol. 91 (2001) 1041-1047
64. Dechent P., Pouwels P.J., Wilken B., Hanefeld F., and Frahm J. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Am. J. Physiol. 277 (1999) R698-704
65. Adcock K.H., Nedelcu J., Loenneker T., Martin E., Wallimann T., and Wagner B.P. Neuroprotection of creatine supplementation in neonatal rats with transient cerebral hypoxia-ischemia. Dev. Neurosci. 24 (2002) 382-388
66. Andreassen O.A., Dedeoglu A., Ferrante R.J., Jenkins B.G., Ferrante K.L., Thomas M., Friedlich A., Browne S.E., Schilling G., Borchelt D.R., Hersch S.M., Ross C.A., and Beal M.F. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington's disease. Neurobiol. Dis. 8 (2001) 479-491
67. Klivenyi P., Ferrante R.J., Matthews R.T., Bogdanov M.B., Klein A.M., Andreassen O.A., Mueller G., Wermer M., Kaddurah-Daouk R., and Beal M.F. Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat. Med. 5 (1999) 347-350
68. Lawler J.M., Barnes W.S., Wu G., Song W., and Demaree S. Direct antioxidant properties of creatine. Biochem. Biophys. Res. Commun. 290 (2002) 47-52
69. Sullivan P.G., Geiger J.D., Mattson M.P., and Scheff S.W. Dietary supplement creatine protects against traumatic brain injury. Ann. Neurol. 48 (2000) 723-729
70. Duke A.M., and Steele D.S. Effects of creatine phosphate on Ca2+ regulation by the sarcoplasmic reticulum in mechanically skinned rat skeletal muscle fibres. J. Physiol. 517 Pt 2 (1999) 447-458
71. Louis M., Raymackers J.M., Debaix H., Lebacq J., and Francaux M. Effect of creatine supplementation on skeletal muscle of mdx mice. Muscle Nerve 29 (2004) 687-692
72. Pulido S.M., Passaquin A.C., Leijendekker W.J., Challet C., Wallimann T., and Ruegg U.T. Creatine supplementation improves intracellular Ca2+ handling and survival in mdx skeletal muscle cells. FEBS Lett. 439 (1998) 357-362
73. Xu C.J., Klunk W.E., Kanfer J.N., Xiong Q., Miller G., and Pettegrew J.W. Phosphocreatine-dependent glutamate uptake by synaptic vesicles. A comparison with ATP-dependent glutamate uptake. J. Biol. Chem. 271 (1996) 13435-13440
74. Bender A., Auer D.P., Merl T., Reilmann R., Saemann P., Yassouridis A., Bender J., Weindl A., Dose M., Gasser T., and Klopstock T. Creatine supplementation lowers brain glutamate levels in Huntington's disease. J. Neurol. 252 (2005) 36-41
75. Dedeoglu A., Kubilus J.K., Yang L., Ferrante K.L., Hersch S.M., Beal M.F., and Ferrante R.J. Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J. Neurochem. 85 (2003) 1359-1367
76. Ferrante R.J., Andreassen O.A., Jenkins B.G., Dedeoglu A., Kuemmerle S., Kubilus J.K., Kaddurah-Daouk R., Hersch S.M., and Beal M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease. J. Neurosci. 20 (2000) 4389-4397
77. Klivenyi P., Calingasan N.Y., Starkov A., Stavrovskaya I.G., Kristal B.S., Yang L., Wieringa B., and Beal M.F. Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase. Neurobiol. Dis. 15 (2004) 610-617
78. Malcon C., Kaddurah-Daouk R., and Beal M.F. Neuroprotective effects of creatine administration against NMDA and malonate toxicity. Brain Res. 860 (2000) 195-198
79. Matthews R.T., Ferrante R.J., Klivenyi P., Yang L., Klein A.M., Mueller G., Kaddurah-Daouk R., and Beal M.F. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp. Neurol. 157 (1999) 142-149
80. Matthews R.T., Yang L., Jenkins B.G., Ferrante R.J., Rosen B.R., Kaddurah-Daouk R., and Beal M.F. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington's disease. J. Neurosci. 18 (1998) 156-163
81. Zhu S., Li M., Figueroa B.E., Liu A., Stavrovskaya I.G., Pasinelli P., Beal M.F., Brown Jr. R.H., Kristal B.S., Ferrante R.J., and Friedlander R.M. Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J. Neurosci. 24 (2004) 5909-5912
82. Passaquin A.C., Renard M., Kay L., Challet C., Mokhtarian A., Wallimann T., and Ruegg U.T. Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice. Neuromuscul. Disord. 12 (2002) 174-182
83. Barisic N., Bernert G., Ipsiroglu O., Stromberger C., Muller T., Gruber S., Prayer D., Moser E., Bittner R.E., and Stockler-Ipsiroglu S. Effects of oral creatine supplementation in a patient with MELAS phenotype and associated nephropathy. Neuropediatrics 33 (2002) 157-161
84. Tarnopolsky M.A., Roy B.D., and MacDonald J.R. A randomized, controlled trial of creatine monohydrate in patients with mitochondrial cytopathies. Muscle Nerve 20 (1997) 1502-1509
85. Borchert A., Wilichowski E., and Hanefeld F. Supplementation with creatine monohydrate in children with mitochondrial encephalomyopathies. Muscle Nerve 22 (1999) 1299-1300
86. Komura K., Hobbiebrunken E., Wilichowski E.K., and Hanefeld F.A. Effectiveness of creatine monohydrate in mitochondrial encephalomyopathies. Pediatr. Neurol. 28 (2003) 53-58
87. Komura K., Nakano K., Ishigaki K., Tarashima M., Nakayama T., Sasaki K., Saito K., and Osawa M. Creatine monohydrate therapy in a Leigh syndrome patient with A8344G mutation. Pediatr. Int. 48 (2006) 409-412
88. Klopstock T., Querner V., Schmidt F., Gekeler F., Walter M., Hartard M., Henning M., Gasser T., Pongratz D., Straube A., Dieterich M., and Muller-Felber W. A placebo-controlled crossover trial of creatine in mitochondrial diseases. Neurology 55 (2000) 1748-1751
89. Kornblum C., Schroder R., Muller K., Vorgerd M., Eggers J., Bogdanow M., Papassotiropoulos A., Fabian K., Klockgether T., and Zange J. Creatine has no beneficial effect on skeletal muscle energy metabolism in patients with single mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS crossover study. Eur. J. Neurol. 12 (2005) 300-309
90. Baker S.K., and Tarnopolsky M.A. Statin-associated neuromyotoxicity. Drugs Today (Barc) 41 (2005) 267-293
91. Diaczok B.J., and Shali R. Statins unmasking a mitochondrial myopathy: a case report and proposed mechanism of disease. South Med. J. 96 (2003) 318-320
92. Baker S.K., Vladutiu G.D., Peltier W.L., Isackson P.J., and Tarnopolsky M.A. Metabolic myopathies discovered during investigations of statin myopathy. Can. J. Neurol. Sci. 35 (2008) 94-97
93. Goda S., Hamada T., Ishimoto S., Kobayashi T., Goto I., and Kuroiwa Y. Clinical improvement after administration of coenzyme Q10 in a patient with mitochondrial encephalomyopathy. J. Neurol. 234 (1987) 62-63
94. Haas R.H. The evidence basis for coenzyme Q therapy in oxidative phosphorylation disease. Mitochondrion 7 (2007) S136-145 Suppl
95. Ihara Y., Namba R., Kuroda S., Sato T., and Shirabe T. Mitochondrial encephalomyopathy (MELAS): pathological study and successful therapy with coenzyme Q10 and idebenone. J. Neurol. Sci. 90 (1989) 263-271
96. Matthews P.M., Ford B., Dandurand R.J., Eidelman D.H., O'Connor D., Sherwin A., Karpati G., Andermann F., and Arnold D.L. Coenzyme Q10 with multiple vitamins is generally ineffective in treatment of mitochondrial disease. Neurology 43 (1993) 884-890
97. Suzuki Y., Kadowaki H., Atsumi Y., Hosokawa K., Katagiri H., Kadowaki T., Oka Y., Uyama K., Mokubo A., Asahina T., et al. A case of diabetic amyotrophy associated with 3243 mitochondrial tRNA(leu; UUR) mutation and successful therapy with coenzyme Q10. Endocr. J. 42 (1995) 141-145
98. Shults C.W., Flint Beal M., Song D., and Fontaine D. Pilot trial of high dosages of coenzyme Q10 in patients with Parkinson's disease. Exp. Neurol. 188 (2004) 491-494
99. Shults C.W., Oakes D., Kieburtz K., Beal M.F., Haas R., Plumb S., Juncos J.L., Nutt J., Shoulson I., Carter J., Kompoliti K., Perlmutter J.S., Reich S., Stern M., Watts R.L., Kurlan R., Molho E., Harrison M., and Lew M. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch. Neurol. 59 (2002) 1541-1550
100. Artuch R., Brea-Calvo G., Briones P., Aracil A., Galvan M., Espinos C., Corral J., Volpini V., Ribes A., Andreu A.L., Palau F., Sanchez-Alcazar J.A., Navas P., and Pineda M. Cerebellar ataxia with coenzyme Q10 deficiency: diagnosis and follow-up after coenzyme Q10 supplementation. J. Neurol. Sci. 246 (2006) 153-158
101. Lalani S.R., Vladutiu G.D., Plunkett K., Lotze T.E., Adesina A.M., and Scaglia F. Isolated mitochondrial myopathy associated with muscle coenzyme Q10 deficiency. Arch. Neurol. 62 (2005) 317-320
102. Rustin P., Rotig A., Munnich A., and Sidi D. Heart hypertrophy and function are improved by idebenone in Friedreich's ataxia. Free Radic. Res. 36 (2002) 467-469
103. Hausse A.O., Aggoun Y., Bonnet D., Sidi D., Munnich A., Rotig A., and Rustin P. Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart 87 (2002) 346-349
104. Rustin P., von Kleist-Retzow J.C., Chantrel-Groussard K., Sidi D., Munnich A., and Rotig A. Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet 354 (1999) 477-479
105. Ikejiri Y., Mori E., Ishii K., Nishimoto K., Yasuda M., and Sasaki M. Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 47 (1996) 583-585
106. Napolitano A., Salvetti S., Vista M., Lombardi V., Siciliano G., and Giraldi C. Long-term treatment with idebenone and riboflavin in a patient with MELAS. Neurol. Sci. 21 (2000) S981-982
107. Kobayashi M., Morishita H., Sugiyama N., Yokochi K., Nakano M., Wada Y., Hotta Y., Terauchi A., and Nonaka I. Two cases of NADH-coenzyme Q reductase deficiency: relationship to MELAS syndrome. J. Pediatr. 110 (1987) 223-227
108. Bugiani M., Lamantea E., Invernizzi F., Moroni I., Bizzi A., Zeviani M., and Uziel G. Effects of riboflavin in children with complex II deficiency. Brain Dev. 28 (2006) 576-581
109. Bernsen P.L., Gabreels F.J., Ruitenbeek W., and Hamburger H.L. Treatment of complex I deficiency with riboflavin. J. Neurol. Sci. 118 (1993) 181-187
110. Bernsen P.L., Gabreels F.J., Ruitenbeek W., Sengers R.C., Stadhouders A.M., and Renier W.O. Successful treatment of pure myopathy, associated with complex I deficiency, with riboflavin and carnitine. Arch. Neurol. 48 (1991) 334-338
111. Scholte H.R., Busch H.F., Bakker H.D., Bogaard J.M., Luyt-Houwen I.E., and Kuyt L.P. Riboflavin-responsive complex I deficiency. Biochim. Biophys. Acta 1271 (1995) 75-83
112. Bakker H.D., Scholte H.R., Jeneson J.A., Busch H.F., Abeling N.G., and van Gennip A.H. Vitamin-responsive complex I deficiency in a myopathic patient with increased activity of the terminal respiratory chain and lactic acidosis. J. Inherit. Metab. Dis. 17 (1994) 196-204
113. Oguro H., Iijima K., Takahashi K., Nagai A., Bokura H., Yamaguchi S., and Kobayashi S. Successful treatment with succinate in a patient with MELAS. Intern. Med. 43 (2004) 427-431
114. Schoenen J., Jacquy J., and Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 50 (1998) 466-470
115. Sandor P.S., Di Clemente L., Coppola G., Saenger U., Fumal A., Magis D., Seidel L., Agosti R.M., and Schoenen J. Efficacy of coenzyme Q10 in migraine prophylaxis: a randomized controlled trial. Neurology 64 (2005) 713-715
116. Magis D., Ambrosini A., Sandor P., Jacquy J., Laloux P., and Schoenen J. A randomized double-blind placebo-controlled trial of thioctic acid in migraine prophylaxis. Headache 47 (2007) 52-57
117. Marriage B.J., Clandinin M.T., Macdonald I.M., and Glerum D.M. Cofactor treatment improves ATP synthetic capacity in patients with oxidative phosphorylation disorders. Mol. Genet. Metab. 81 (2004) 263-272
118. Trifunovic A., Wredenberg A., Falkenberg M., Spelbrink J.N., Rovio A.T., Bruder C.E., Bohlooly Y.M., Gidlof S., Oldfors A., Wibom R., Tornell J., Jacobs H.T., and Larsson N.G. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429 (2004) 417-423
119. Wredenberg A., Wibom R., Wilhelmsson H., Graff C., Wiener H.H., Burden S.J., Oldfors A., Westerblad H., and Larsson N.G. Increased mitochondrial mass in mitochondrial myopathy mice. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 15066-15071
120. Peterson P.L. The treatment of mitochondrial myopathies and encephalomyopathies. Biochim. Biophys. Acta 1271 (1995) 275-280